The protective effect of rheumatic disease agents in COVID-19.
Best Pract Res Clin Rheumatol
; 35(1): 101659, 2021 03.
Article
in English
| MEDLINE | ID: covidwho-1060265
ABSTRACT
Several immunosuppressive therapies have been investigated as potential treatments for patients with severe and critical coronavirus disease 2019 (COVID-19). Notable examples include corticosteroids, interleukin 6 (IL-6), interleukin 1 (IL-1), Janus kinase (JAK), and tumor necrosis factor alpha (TNF-α) inhibitors. The aim of this narrative review is to analyze the mechanistic rationale and available evidence for these selected anti-rheumatic drugs for the treatment of COVID-19. Currently, only corticosteroids have consistently proven to be effective in decreasing mortality and are recommended in clinical guidelines for the treatment of severe and critical COVID-19. Multiple randomized controlled trials (RCTs) are ongoing to determine the role of other immunosuppressants.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Rheumatic Diseases
/
Antirheumatic Agents
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
/
Reviews
Limits:
Humans
Language:
English
Journal:
Best Pract Res Clin Rheumatol
Journal subject:
Rheumatology
Year:
2021
Document Type:
Article
Affiliation country:
J.berh.2021.101659
Similar
MEDLINE
...
LILACS
LIS